Maternal–fetal medicine

Tending to a growing need for specialized solutions FertiClinic Fertilization Centre inaugurates a new state-of-the-art facility in Sahara Healthcare City

Retrieved on: 
Wednesday, August 2, 2023
Communication, Reproductive medicine, Partnership, TESE, Consultant, Obstetrics and gynaecology, Hope, Research, IVF, Maternal–fetal medicine, IUI, Assisted reproductive technology, Medical director, Patient, Fertility, ICSI, Happiness, Gynaecology, Birth control, Nursing, Obstetrics, Infertility, Sahara Mall (Riyadh)

These figures highlight a growing need for specialized solutions.

Key Points: 
  • These figures highlight a growing need for specialized solutions.
  • As the demand for fertility treatments continues to rise, FertiClinic Fertilization Centre, renowned for its exceptional fertility treatments across the UAE, inaugurated its new state-of-the-art facility at Sahara Healthcare City, Sahara Mall, Sharjah.
  • With a track record of high success rates in assisted reproductive techniques, FertiClinic aims to offer its specialized services to families seeking fertility solutions.
  • The clinic's strategic location at Sahara Healthcare City, Sahara Mall, Floor No.7, Al Nahda Street, Sharjah, provides patients with easy access to world-class medical facilities in a community-oriented healthcare setting.

Tending to a growing need for specialized solutions FertiClinic Fertilization Centre inaugurates a new state-of-the-art facility in Sahara Healthcare City

Retrieved on: 
Wednesday, August 2, 2023
Communication, Reproductive medicine, Partnership, TESE, Consultant, Obstetrics and gynaecology, Hope, Research, IVF, Maternal–fetal medicine, IUI, Assisted reproductive technology, Medical director, Patient, Fertility, ICSI, Happiness, Gynaecology, Birth control, Nursing, Obstetrics, Infertility, Sahara Mall (Riyadh)

These figures highlight a growing need for specialized solutions.

Key Points: 
  • These figures highlight a growing need for specialized solutions.
  • As the demand for fertility treatments continues to rise, FertiClinic Fertilization Centre, renowned for its exceptional fertility treatments across the UAE, inaugurated its new state-of-the-art facility at Sahara Healthcare City, Sahara Mall, Sharjah.
  • With a track record of high success rates in assisted reproductive techniques, FertiClinic aims to offer its specialized services to families seeking fertility solutions.
  • The clinic's strategic location at Sahara Healthcare City, Sahara Mall, Floor No.7, Al Nahda Street, Sharjah, provides patients with easy access to world-class medical facilities in a community-oriented healthcare setting.

New Scientific Research Funding Available to Eliminate Pre-Term Deliveries from Preeclampsia

Retrieved on: 
Wednesday, July 5, 2023
Letter, Survivor, HELLP, Partnership, Pregnancy, Society, Registry, Therapy, Society for Maternal-Fetal Medicine, Friends, Research, Maternal–fetal medicine, Pre-eclampsia, Marker beacon, HELLP syndrome, Hypertension, Infant, Diagnosis, Family, Visions (Grant Green album), Pharmaceutical industry, Tourism

MELBOURNE, Fla., July 5, 2023 /PRNewswire/ -- The Preeclampsia Foundation is seeking Letters of Intent for the Peter Joseph Pappas Research Grants funding program, designed to accelerate preeclampsia research.

Key Points: 
  • MELBOURNE, Fla., July 5, 2023 /PRNewswire/ -- The Preeclampsia Foundation is seeking Letters of Intent for the Peter Joseph Pappas Research Grants funding program, designed to accelerate preeclampsia research.
  • The ultimate goal of this grant program is to drive research that will eliminate the delivery of pre-term babies as an intervention for severe preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy.
  • Eligible applicants should focus on the current research gaps identified through a 2020 preeclampsia workshop jointly sponsored by the Preeclampsia Foundation and the Society for Maternal Fetal Medicine.
  • The Peter Joseph Pappas Research Grants program adds to the Preeclampsia Foundation's portfolio of research programs including the Vision Grant program for young investigators, and the Preeclampsia Registry, a dynamic database of research participants including preeclampsia and HELLP syndrome survivors, family members, and controls (unaffected individuals).

New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Retrieved on: 
Monday, June 26, 2023
EOS, HDFN, Fetus, Umbilical cord, European Medicines Agency, Janssen, Janssen Pharmaceuticals, Patient, Memorial Hermann–Texas Medical Center, Risk, Immunoglobulin G, Disease, Infant, IUT, Neonatal Fc receptor, UNITY, Tissue, Ohio State University, Hydrops, University, Dell Medical School, Gestational age, EMA, SPRING, Diagnosis, FDA, FC, Placenta, HOUSE, Health, Maternal–fetal medicine, Child, Șaeș, Blood, Immune system, Mortality, Johnson & Johnson, Epidural hematoma, Anemia, Infection, Edema, Clinical trial, Fast Track, Mount Sinai Hospital, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Birth control, Dietary supplement

SPRING HOUSE, Pa., June 26, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive results from the proof-of-concept Phase 2 open-label UNITY clinical trial for the treatment of pregnant individuals at high risk of early-onset severe (EOS) hemolytic disease of the fetus and newborn (HDFN).1 A statistically significant (54 percent [n=7/13]) proportion of participants who received nipocalimab achieved the primary endpoint of a live birth at or after gestational age of 32 weeks without intrauterine transfusions (IUTs)1,a compared to the historic reference point of 10 percent, which was derived from published and unpublished data.2-5,b Among the seven participants who achieved the primary endpoint, the median gestational age at delivery was 37 and 1/7 weeks.6 This study demonstrates the potential for nipocalimab to help address the underlying disease mechanism of EOS HDFN.1 If approved, nipocalimab would be the first anti-neonatal Fc receptor (FcRn) treatment and the first approved non-surgical intervention for pregnancies at high risk of HDFN in the U.S.7 These data will be presented for the first time at the Fetal Medicine Foundation World Congress in Valencia, Spain on June 26, 2023.1 Janssen is planning a pivotal Phase 3 trial for nipocalimab in pregnancies at risk for severe HDFN.

Key Points: 
  • "There is a significant unmet need to help address the serious and life-threatening health consequences of HDFN.
  • "These Phase 2 UNITY data in high-risk pregnancies demonstrated the important role that nipocalimab, an FcRn blocking antibody, may play in preventing the transfer of maternal alloantibodies through the placenta, thereby offering a potential treatment option for this devastating disease."
  • A conservative benchmark of 10 percent of patients not requiring an IUT was chosen to account for uncertainties in the accuracy and representation of the underlying data.2
    d.  Dr. Kenneth Moise is a paid consultant for Janssen.
  • He has not been compensated for any media work.

Allegheny Health Network Names Devon M. Ramaeker, MD, Division Chief of Maternal Fetal Medicine

Retrieved on: 
Monday, April 3, 2023
Anomaly scan, Pregnancy, Obesity, Placenta, University, Diabetes, American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine, Education, Gestational diabetes, Fetus, State Correctional Institution – Pittsburgh, Cardiovascular disease, Maternal–fetal medicine, Research, Drexel University, Doctor of Philosophy, Nicu Ceaușescu, AHN, Division, Patient, UPMC Magee-Womens Hospital, Physician, University of South Dakota Sanford School of Medicine, Genetic testing, Obstetrics, Diagnosis, Nursing care plan, Luke the Evangelist, Health, American College, Gynaecology, Allegheny Health Network, Empowerment, Kidney disease, Dietary supplement, Hospital, Medical imaging, Nursing, MFM, MD

PITTSBURGH, Pa., April 3, 2023 /PRNewswire-PRWeb/ -- Allegheny Health Network (AHN) today announced the appointment of Devon M. Ramaeker, MD, to Division Chief of Maternal Fetal Medicine (MFM) within AHN Women's Institute.

Key Points: 
  • Allegheny Health Network today announced the appointment of Devon M. Ramaeker, MD, to Division Chief of Maternal Fetal Medicine within AHN Women's Institute
    PITTSBURGH, Pa., April 3, 2023 /PRNewswire-PRWeb/ -- Allegheny Health Network (AHN) today announced the appointment of Devon M. Ramaeker, MD , to Division Chief of Maternal Fetal Medicine (MFM) within AHN Women's Institute.
  • Dr. Ramaeker joined AHN in 2022, having previously served as the medical director of MFM at St. Luke's Health System in Kansas City, Missouri.
  • MFM physicians have advanced training in diagnosing and treating complex pregnancies that involve chronic health or genetic conditions, fetal abnormalities, and/or any unforeseen complication to the patient or fetus.
  • Throughout her career, Dr. Ramaeker has advanced an integrated, multidisciplinary approach to managing the complex health needs of this patient population.

High-Risk Pregnancy Expert Joins NYU Langone Health as Director of Maternal-Fetal Medicine

Retrieved on: 
Tuesday, March 21, 2023
Stanley, Obstetrics, NYU Langone Health, NYU, New York University Grossman School of Medicine, OBGYN, Maternal–fetal medicine, Rutgers University, Robert Wood Johnson Medical School, Division, Gynaecology, Medicine, Quality assurance, Health, MPH, Nursing, Birth control, MD

NEW YORK, March 21, 2023 /PRNewswire/ -- Justin S. Brandt, MD, a nationally recognized specialist in managing high-risk pregnancies, has joined NYU Langone Health as director of the Division of Maternal-Fetal Medicine in the Department of Obstetrics & Gynecology.

Key Points: 
  • NEW YORK, March 21, 2023 /PRNewswire/ -- Justin S. Brandt, MD, a nationally recognized specialist in managing high-risk pregnancies, has joined NYU Langone Health as director of the Division of Maternal-Fetal Medicine in the Department of Obstetrics & Gynecology.
  • "Maternal Fetal Medicine is an integral part of obstetrical care and I'm thrilled to have a nationally known expert like Dr. Brandt leading our team.
  • I am confident he will continue to help ensure the best possible outcomes for pregnant people and their babies that require high risk care at NYU Langone."
  • "I am dedicated to providing evidence-based, comprehensive, and inclusive care and am thrilled to join NYU Langone as the new director of maternal-fetal medicine," said Dr. Brandt.

Samsung Introduces Premium Women’s Health Ultrasound

Retrieved on: 
Wednesday, February 8, 2023
Hardware, Health Technology, Data Management, Other Health, Technology, Radiology, General Health, Medical Devices, Women, Hospitals, Baby, Maternity, Wearables, Mobile Technology, Other Technology, Consumer, Health, Society, Woman, Circulant matrix, 2D, Samsung, Diagnosis, Artificial intelligence, Sale, Maternal–fetal medicine, FDA, HERA, Multimedia, Gynaecology, Obstetrics, 3D, Medical imaging, Medical device

View the full release here: https://www.businesswire.com/news/home/20230208005629/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230208005629/en/
    The HERA W10 Elite features an ergonomic-friendly design and is optimized with updated imaging capabilities to drive diagnostic confidence.
  • (Photo: Business Wire)
    “Women’s health is a fast-growing field that requires state-of-the-art equipment for patient care.
  • The HERA W10 Elite will bring visionary change to Obstetrics and Gynecology with sophisticated image processing and an ergonomic-friendly design,” said Tracy Bury, Women's Health Ultrasound Business Leader, Boston Imaging.
  • Samsung is committed to bringing new and updated women’s health-focused ultrasound systems to market to remain true to its pledge to support the life-long healthcare of women.

AHN Customizes Iconic Candy Hearts to Spread Awareness this Valentine's Day

Retrieved on: 
Friday, February 10, 2023
American Heart Association, Cardiovascular disease, Allegheny Health Network, Woman, AHN, Division, Patient, Heart, Drop box, Maternal–fetal medicine, Exercise, Cancer, Candy, MD, Dietary supplement

PITTSBURGH, Feb. 10, 2023 /PRNewswire-PRWeb/ -- For more than a century, candy "conversation hearts" have been an annual staple of Valentine's Day festivities. This year, in a nod to National Heart Month and the American Heart Association's "Go Red for Women" initiative, Allegheny Health Network (AHN) is repurposing the iconic sweet treat to raise awareness of cardiovascular disease among women.

Key Points: 
  • PITTSBURGH, Feb. 10, 2023 /PRNewswire-PRWeb/ -- For more than a century, candy "conversation hearts" have been an annual staple of Valentine's Day festivities.
  • This year, in a nod to National Heart Month and the American Heart Association's "Go Red for Women" initiative, Allegheny Health Network (AHN) is repurposing the iconic sweet treat to raise awareness of cardiovascular disease among women.
  • AHN Cardiovascular Institute and AHN Women's Institute collaborated on the awareness initiative.
  • "We're extremely excited about this awareness campaign as the candy kiosks are an interactive, inviting way to reach women with this critically important call to action."

New Preeclampsia Research Funded to Investigate Genetic Targets to Develop Potential Therapeutics

Retrieved on: 
Wednesday, February 8, 2023
Society, Boston Medical Center, Boston University, Cone Health Women's Hospital, Boston University Chobanian & Avedisian School of Medicine, Defence Scientific Advisory Council, Protein, Health, Pre-eclampsia, PRIME, HELLP, Division, Hospital, Infant, Cell, Fetus, Friends, Research, Family, Risk, Maternal–fetal medicine, Associate, APOL1, Apolipoprotein L1, Pregnancy, Partnership, SAN, EMPOWER, HELLP syndrome, L1, Hypertension, Visions (Grant Green album), Gynaecology, Infertility, Pharmaceutical industry, Tourism, Medicine, MD, Obstetrics

Based on the recommendations of its Scientific Advisory Council, the Preeclampsia Foundation awarded a grant totaling $99,994 USD to Wendy Kuohung, MD of Boston University.

Key Points: 
  • Based on the recommendations of its Scientific Advisory Council, the Preeclampsia Foundation awarded a grant totaling $99,994 USD to Wendy Kuohung, MD of Boston University.
  • The study is designed to potentially accelerate discovery of therapies for preeclampsia by designing placental cell lines that express variants of the APOL1 gene for drug screening.
  • "We lost our son Peter due to preeclampsia following a 29-week delivery in 2015," explained Lauren Pappas.
  • The Peter Joseph Pappas Research Grants program adds to the Preeclampsia Foundation's portfolio of research programs including the Vision Grant program for young investigators, PRIME for health services research, and EMPOWER, which helps build research capacity in low- and middle-income countries.

HMP Global's SAWC Spring | WHS announces record number of wound care abstract submissions for 2023 meeting

Retrieved on: 
Wednesday, January 25, 2023
Diamond, University, Pediatric surgery, MEDLINE, Marketing, Poster, Chin Na, Education, WHS, Student, Knowledge, Surgeon, Abstract, Partnership, Wound healing, Hospital, Leonard M. Miller School of Medicine, Biochemistry, University of Arizona, DLS, Physician, SAWC, Maternal–fetal medicine, Learning, Patient, Biology, Regeneration, Therapy, Research, Wound, Pharmaceutical industry, Nursing, Dermatology

MALVERN, Pa., Jan. 25, 2023 /PRNewswire-PRWeb/ -- HMP Global, the leading omnichannel healthcare events and education company, today announced that its 2023 Symposium on Advanced Wound Care (SAWC) Spring and Wound Healing Society (WHS) received a record-breaking number of abstract submissions for the event taking place April 26-30, strengthened by a new partnership co-locating the symposium with the Diabetic Limb Salvage conference.

Key Points: 
  • Symposium participants will have access to 450 posters featuring late-breaking wound care research, new advances, strategies, and techniques to improve care and outcomes for patients.
  • In addition to presenting posters in person at SAWC Spring | WHS | DLS, wound care researchers can elevate their work further by submitting abstracts for publication in the field's preeminent, peer-reviewed journal WOUNDS , focusing on the latest advances in wound care and wound research.
  • "The record-breaking number of abstract submissions this year is a testament to the dedication of the wound care community to advancing their knowledge and skills," said Tiffney Oliver, Vice President, Wound Care Learning Network, HMP Education.
  • "For our 2023 meeting, we are excited to offer a world-class lineup of educational sessions as well as a record number of abstracts about the latest research in wound care."